Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Pacira Pharmaceuticals reports record revenues and strategic growth plans

Pacira Pharmaceuticals delivered strong financial performance in 2024, driven by key product milestones and strategic initiatives. While facing challenges in a competitive market and evolving healthcare landscape, the company's disciplined approach to growth and innovation remains a strength. With a focus on expanding market presence, optimizing product offerings, and prudent capital allocation, Pacira is poised for continued success.

Pacira Pharmaceuticals (PCRX) excels in Q2 2025, driving growth and value

Pacira Pharmaceuticals (PCRX) showcased robust performance in Q2 2025, driven by EXPAREL's growth and improved financial metrics. Strategic partnerships, disciplined capital allocation, and a focus on market access highlight the company's proactive approach to growth. While challenges exist in pipeline development and market access, Pacira's strong performance sets a solid foundation for future opportunities.

Pacira Pharmaceuticals reports robust Q3 growth and strategic advancements

Pacira Pharmaceuticals delivered solid financial performance in Q3 2025, driven by revenue growth, margin improvement, and strategic investments in product development. The company's focus on expanding market access for EXPAREL, advancing pipeline products, and optimizing costs positions it well for sustained growth. Despite facing challenges in pricing and competition, Pacira's strong financial position, innovative pipeline, and shareholder-friendly initiatives present promising opportunities for future success.

Pacira Pharmaceuticals reports strong Q4 performance and outlines growth strategies

Pacira Pharmaceuticals (PCRX) had a strong Q4 2025 performance with revenue growth and improved margins. EXPAREL's performance, strategic partnerships, and pipeline progress indicate future growth potential. Challenges include managing expenses and meeting financial guidance, while opportunities lie in partnerships and market growth. The company's capital deployment strategy and focus on top-line growth position it for future success.

Pacira Pharmaceuticals (PCRX) excels in Q1 2026, poised for sustained growth

Pacira Pharmaceuticals (PCRX) delivered a strong Q1 2026 performance driven by EXPAREL's growth and strategic initiatives. With a focus on innovation, market expansion, and financial discipline, PCRX is well-positioned to capitalize on growth opportunities and navigate industry challenges. Investors can look forward to continued revenue growth, pipeline advancements, and shareholder value creation as PCRX maintains its momentum in the pharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Brisbane, CA.